Contact Us 联系我们
Contact Us 联系我们
Contact Us 联系我们


Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements

31/05/2019Appendix 3BDownload
14/05/2019Bisantrene AML trial to start in IsraelDownload
24/04/2019Bisantrene IND UpdateDownload
12/04/2019Appendix 4C - quarterlyDownload
25/03/2019Race files Bisantrene IND with FDADownload
13/03/2019Appendix 3BDownload
27/02/2019Appendix 4D & Half-Year Financial StatementsDownload
25/02/2019Principal Investigator appointed for BisantreneDownload
14/02/2019Appendix 3Y-Dr William GarnerDownload
12/02/2019Change in substantial holdingDownload
1  2  3  4  5  6  



Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2019 Race Oncology. Website By Multiplier